The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
Peter Dubsky, Christian F. Singer, Daniel Egle, Viktor Wette, Edgar Petru, Marija Balić, Angelika Pichler, Richard Greil, Andreas Petzer, Zsuzsanna Bagó-Horváth, Christian Fesl, Stephanie Meek, Ralf Kronenwett, Margaretha Rudas, Michael Gnant, Martin Filipits
Topics & Concepts
MedicineOncologyBreast cancerInternal medicineHuman Epidermal Growth Factor Receptor 2ChemotherapyHormone receptorRandomized controlled trialHER2 negativeCancerMetastatic breast cancerBreast Cancer Treatment StudiesBreast Lesions and CarcinomasAdvanced Breast Cancer Therapies